Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
NEW BRUNSWICK, N.J., January 29, 2020 – Johnson & Johnson today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, the Company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others to screen a library of antiviral therapies. Identifying compounds with antiviral activity against 2019-nCoV may contribute to providing immediate relief to the current outbreak.“J&J has a long-standing commitment to fight established and emerging epidemics and is supporting global efforts where we can make the greatest impact. We are collaborating with regulators, healthcare organizations, institutions and communities worldwide to help ensure our research platforms, existing science and outbreak expertise can be maximized to stem this public health threat,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. “This latest outbreak of a novel pathogen once again reinforces the importance of investing in preparedness, surveillance and response to ensure the world remains ahead of potential pandemic threats.” The vaccine program will leverage Janssen’s AdVac® and PER.C6® technologies that provide the ability to rapidly upscale production of the optimal vaccine candidate. These are the same techn...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
More News: Academies | Allergy & Immunology | Australia Health | Brain | Cambodia Health | Canada Health | Cancer & Oncology | Cardiology | Cardiovascular | Centers for Disease Control and Prevention (CDC) | China Health | Congo Health | Coronavirus | COVID-19 | Databases & Libraries | Ebola | Ebola Vaccine | Environmental Health | Epidemics | Epidemiology | France Health | Germany Health | Government | Health Management | Heart | Hong Kong Health | Hospitals | Hypertension | Infectious Diseases | International Medicine & Public Health | Japan Health | Kaletra | Laboratory Medicine | Learning | Legislation | Malaysia Health | Nepal Health | Neurology | Neuroscience | Norvir | Outbreaks | Pandemics | Pharmaceuticals | Prezista | Pulmonary Hypertension | Respiratory Medicine | Rwanda Health | SARS | Science | Singapore Health | Sri Lanka Health | Taiwan Health | Thailand Health | Universities & Medical Training | Vaccines | Vietnam Health | Virology | WHO | Zika Virus